US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

First Tracks Biotherapeutics, Inc. - Ordinary Shares (NQ:TRAX)

34.05 +2.20 (+6.91%)
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about First Tracks Biotherapeutics, Inc. - Ordinary Shares

News headline image
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
From First Tracks Biotherapeutics Inc
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
From First Tracks Biotherapeutics Inc
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
From First Tracks Biotherapeutics Inc
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
From First Tracks Biotherapeutics Inc
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
From First Tracks Biotherapeutics Inc
Via GlobeNewswire
News headline image
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
From First Tracks Biotherapeutics Inc
Via GlobeNewswire